ABCL — AbCellera Biologics Inc.
Is ABCL overbought or oversold? Here is the current MarketMoodz read.
AbCellera Biologics Inc. (ABCL) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $11.03. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$11.03
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
AbCellera Biologics Inc. (ABCL) is positioned as an antibody discovery platform company with a services and partnership model that can generate milestone, license and royalty revenues. The business benefits from platform-enabled differentiation and potential tailwinds from pharma consolidation and demand for outsourced discovery, but near-term performance hinges on collaborator activity, milestone timing, and cash runway. Competitive pressures, partner concentration, and the lumpy nature of milestone recognition create material execution and financial risk. Given a measured market tone and selective support for growth names, the stock may trade with limited volatility near current levels absent a clear partner milestone or material new collaboration.
Key factors
- Platform strength: Proprietary antibody discovery platform and partnerships provide a differentiated services/revenue stream versus early-stage single-product biotechs.
- Partnerships and collaborator revenue: Existing collaborations can generate milestone and license receipts; near-term revenue visibility depends on partner activity and milestone timing.
- Cash runway and capital structure: As a small/mid-cap biotech-like services company, liquidity and cash burn dynamics are key determinants of near-term execution risk.
- Market backdrop: Measured risk-on tone and selective support for growth names could sustain investor interest in innovative biotech platforms like AbCellera, but flows are cautious.
- Sector tailwinds: Large-cap pharma defensive flows and consolidation into specialty franchises may increase demand for outsourced discovery services and M&A interest.
- Execution and commercialization optionality: Ability to convert discovery work into long-term, royalty-bearing assets or repeat service contracts will materially affect valuation.
Risks
- Revenue concentration: Reliance on a limited number of large collaborators could lead to volatile revenue if partners delay programs or change priorities.
- Clinical/regulatory and scientific risk: Downstream clinical failures or disappointing translational results from partnered programs would reduce milestone prospects and investor appetite.
- Competitive pressure: Competing discovery platforms and CROs could compress pricing or reduce win rates for new collaborations.
- Capital markets and dilution: Need for additional capital to fund growth or bridge cash burn could result in dilution at unfavorable prices.
- Contract timing and accounting variability: Milestone recognition timing can create lumpy reported results and short-term earnings surprises.
- Broader macro/sector volatility: Rotational flows away from growth/speculative names or sudden market stress could materially depress the share price.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ABCL — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.